Table 1. Distribution of patients, according to treatment (radiation therapy dose) and clinical features.
| RT 50.4Gy(*n = 188) | RT 55.0Gy(n = 77) | χ2 | |||
|---|---|---|---|---|---|
| N | (%) | N | (%) | ||
| Sex | |||||
| Man | 55 | (29.3) | 28 | (36.4) | |
| Woman | 133 | (70.7) | 49 | (63.6) | p = 0.2573 |
| Age (years) | |||||
| <55 | 47 | (25.0) | 19 | (24.7) | |
| 55-59 | 37 | (19.7) | 13 | (16.9) | |
| 60-64 | 35 | (18.6) | 20 | (26.0) | |
| 65-69 | 36 | (19.2) | 12 | (15.6) | |
| ≥70 | 33 | (17.6) | 13 | (16.8) | p = 0.7264 |
| Distance from anal margin (cm) | |||||
| <8 | 124 | (66.0) | 54 | (70.1) | |
| ≥8 | 64 | (34.0) | 23 | (29.9) | p = 0.5114 |
| Time from surgery to radiation therapy (days) | |||||
| <50 | 67 | (38.5) | 16 | (21.3) | |
| 50-56 | 43 | (24.7) | 13 | (17.3) | |
| 57-63 | 27 | (15.5) | 23 | (30.7) | |
| ≥64 | 37 | (21.3) | 23 | (30.7) | p = 0.0032 |
| Unk | 14 | 2 | |||
| TRG | |||||
| 1 | 53 | (28.2) | 20 | (26.0) | |
| 2 | 36 | (19.2) | 20 | (26.0) | |
| 3 | 58 | (30.9) | 29 | (37.7) | |
| 4-5 | 41 | (21.8) | 8 | (10.4) | p = 0.1153 |
TRG, Tumour Regression Grade; RT, radiotherapy; Gy, Gray; unk, unknown
*
93 out of 188 patients (49.5%) received oxaliplatin in addition to fluoropyrimidines